Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI5083 monotherapy · 1 trial · 1 indication
Safety Endpoint
Safety Endpoint
Safety Endpoint
Safety Endpoint
Safety Endpoint
Safety Endpoint
Safety Endpoint
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors |
| Part 2 | EXPERIMENTAL | Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors. |
| Part 3 | EXPERIMENTAL | Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC |
| Name | Type | Description |
|---|---|---|
| MEDI5083 monotherapy | BIOLOGICAL | Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab |
| MEID5083 with Durvalumab or Tremelimumab | BIOLOGICAL | Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab |
| Medi5083 with Durvalumab and Docetaxel | BIOLOGICAL | Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel |
Inclusion Criteria: 1. Age ≥ 18 years at the time of screening or age of consent according to local law 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 3. Histologically or cytologically confirmed metastatic or recurrent tumor types 4. Subjects who have received prior immu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MEDI5083 monotherapy is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated as a potential therapeutic option for patients with advanced solid tumors.
MEDI5083 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting clinical research to evaluate the safety and efficacy of this investigational monoclonal antibody in patients with advanced solid tumors.
MEDI5083 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness. The drug is being studied as a monotherapy for the treatment of advanced solid tumors.
MEDI5083 has been studied in a Phase 1 clinical trial with the identifier NCT03089645. This trial, titled 'MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel,' was conducted in the United States and Australia and enrolled 39 participants with advanced solid tumors. The trial has been completed.
No, MEDI5083 is a distinct investigational monoclonal antibody being developed by AstraZeneca. It is not the same as durvalumab or tremelimumab, which are other monoclonal antibodies. In clinical trials, MEDI5083 has been studied alone and in combination with these other agents to evaluate its potential in treating advanced solid tumors.